PlusVitech has been selected for MassChallenge US Early Cohort 2023. The MassChallenge US Early Stage accelerator is a 3-month mentorship-based programme that provides intensive support, guidance, tools and connectivity to…
We are a biotechnology company developing effective and safe therapeutic treatments for Cancer with the purpose of restoring hope to patients who have no other option. We have been studying cancer and especially its relationship with inflammation for more than 7 years.
Saving lives of patients with cancer and other high-impact diseases with effective, safe, accessible and affordable treatments. With these treatments, we want to prevent suffering, pain and loss of life for millions of people around the world.
We have recently opened an investment round of which we already have part committed. We offer our investors a clear exit strategy. For more information, please contact firstname.lastname@example.org
Which diseases are
PlusVitech treatments for?
Our treatments focus on the repositioning of existing drugs for reuse for other purposes. They have demonstrated effectiveness in lung cancer, breast cancer, lymphoma. We hold 20 international patents (managed by JA Kemp London). The following clinical trials are currently underway:
- Lung cancer: Phase 2 trial (possible Fast Track approval)
How do PlusVitech
Our treatments are based on reestablishing balance in the cells (homeostasis). In the case of cancer, we have clinical evidence that they stop tumor progression and induce cell death (apoptosis).
Therefore, our treatments:
- Are proving in human patients to be effective in clinical trials with patients with diseases such as cancer
- They are non-invasive and non-toxic, and are preferably administered orally
- They are accessible and easily universalizable, as they are based on existing drugs